BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22392125)

  • 1. 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth.
    Gozé C; Bezzina C; Gozé E; Rigau V; Maudelonde T; Bauchet L; Duffau H
    J Neurooncol; 2012 May; 108(1):69-75. PubMed ID: 22392125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
    Labussière M; Idbaih A; Wang XW; Marie Y; Boisselier B; Falet C; Paris S; Laffaire J; Carpentier C; Crinière E; Ducray F; El Hallani S; Mokhtari K; Hoang-Xuan K; Delattre JY; Sanson M
    Neurology; 2010 Jun; 74(23):1886-90. PubMed ID: 20427748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.
    Figarella-Branger D; Bouvier C; de Paula AM; Mokhtari K; Colin C; Loundou A; Chinot O; Metellus P
    J Neurooncol; 2012 Nov; 110(2):205-13. PubMed ID: 22890969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas.
    Ducray F; Mokhtari K; Crinière E; Idbaih A; Marie Y; Dehais C; Paris S; Carpentier C; Dieme MJ; Adam C; Hoang-Xuan K; Duyckaerts C; Delattre JY; Sanson M
    Eur J Cancer; 2011 Mar; 47(5):802-8. PubMed ID: 21194923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
    Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
    J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
    Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
    Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
    Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
    J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas.
    Sonoda Y; Shibahara I; Kawaguchi T; Saito R; Kanamori M; Watanabe M; Suzuki H; Kumabe T; Tominaga T
    Brain Tumor Pathol; 2015 Apr; 32(2):99-104. PubMed ID: 25537428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct IDH1/IDH2 mutation profiles in purely insular versus paralimbic WHO Grade II gliomas.
    Gozé C; Mansour L; Rigau V; Duffau H
    J Neurosurg; 2013 Apr; 118(4):866-72. PubMed ID: 23330999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.
    Gozé C; Blonski M; Le Maistre G; Bauchet L; Dezamis E; Page P; Varlet P; Capelle L; Devaux B; Taillandier L; Duffau H; Pallud J
    Neuro Oncol; 2014 Aug; 16(8):1100-9. PubMed ID: 24847087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH mutations: genotype-phenotype correlation and prognostic impact.
    Wang XW; Ciccarino P; Rossetto M; Boisselier B; Marie Y; Desestret V; Gleize V; Mokhtari K; Sanson M; Labussière M
    Biomed Res Int; 2014; 2014():540236. PubMed ID: 24877111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature.
    Jha P; Suri V; Sharma V; Singh G; Sharma MC; Pathak P; Chosdol K; Jha P; Suri A; Mahapatra AK; Kale SS; Sarkar C
    Exp Mol Pathol; 2011 Aug; 91(1):385-93. PubMed ID: 21569770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis.
    Metellus P; Coulibaly B; Colin C; de Paula AM; Vasiljevic A; Taieb D; Barlier A; Boisselier B; Mokhtari K; Wang XW; Loundou A; Chapon F; Pineau S; Ouafik L; Chinot O; Figarella-Branger D
    Acta Neuropathol; 2010 Dec; 120(6):719-29. PubMed ID: 21080178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas.
    Gleize V; Alentorn A; Connen de Kérillis L; Labussière M; Nadaradjane AA; Mundwiller E; Ottolenghi C; Mangesius S; Rahimian A; Ducray F; ; Mokhtari K; Villa C; Sanson M
    Ann Neurol; 2015 Sep; 78(3):355-74. PubMed ID: 26017892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.
    Takano S; Kato Y; Yamamoto T; Kaneko MK; Ishikawa E; Tsujimoto Y; Matsuda M; Nakai K; Yanagiya R; Morita S; Tsuboi K; Matsumura A
    J Neurooncol; 2012 Jul; 108(3):361-73. PubMed ID: 22396072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of "dual-genotype" IDH-mutant infiltrating gliomas.
    Zepeda-Mendoza CJ; Vaubel RA; Zarei S; Ida CM; Matthews M; Acree S; Raghunathan A; Giannini C; Jenkins RB
    Acta Neuropathol; 2020 Jun; 139(6):1105-1107. PubMed ID: 32170402
    [No Abstract]   [Full Text] [Related]  

  • 19. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
    Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.